![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/7/78/St._Regis_Mohawk_Tribe_Territroy.jpg/640px-St._Regis_Mohawk_Tribe_Territroy.jpg&w=640&q=50)
The St. Regis Mohawk Tribe and Restasis patent
From Wikipedia, the free encyclopedia
Saint Regis Mohawk Tribe v. Mylan Pharms. Inc., 896 F.3d 1322 (Fed. Cir. 2018) is a United States Patent case, decided by the CAFC, deciding whether or not indigenous tribes' sovereign immunity extended to patent lawsuits. In September 2017, the American pharmaceutical company Allergan agreed to transfer six pharmaceutical patents for the ophthalmic form of the drug Restasis to the St. Regis tribe of the Mohawk people.[1] At the time, the St. Regis tribe viewed this blockbuster deal as a new, viable supply of income outside of their primary source, the gambling industry.[2] Following the deal, Allergan received an onslaught of criticism from outside companies and politicians such as Rep. Trey Gowdy, chairman of the Committee on Oversight and Government Reform, who said that the deal, "'impair[s] competition across the pharmaceutical industry.'"[1]
![Thumb image](http://upload.wikimedia.org/wikipedia/commons/thumb/7/78/St._Regis_Mohawk_Tribe_Territroy.jpg/640px-St._Regis_Mohawk_Tribe_Territroy.jpg)
![Thumb image](http://upload.wikimedia.org/wikipedia/commons/thumb/c/c0/Allergan_headquarters.jpg/640px-Allergan_headquarters.jpg)